AU727001B2 - Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS) - Google Patents

Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS) Download PDF

Info

Publication number: AU727001B2
Authority: AU; Australia
Prior art keywords: agent; liver; hyaluronic acid; amount; receptors
Prior art date: 1995-12-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU76878/96A

Other languages

English (en)

Other versions

AU7687896A (en

Inventor

Stefan Gustafson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Jagotec AG

Original Assignee

Hyal Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-01

Filing date

1996-11-29

Publication date

2000-11-30

1995-12-01 Priority claimed from CA002164260A external-priority patent/CA2164260C/en

1996-03-29 Priority claimed from CA 2173037 external-priority patent/CA2173037A1/en

1996-11-29 Application filed by Hyal Pharmaceutical Corp filed Critical Hyal Pharmaceutical Corp

1997-06-27 Publication of AU7687896A publication Critical patent/AU7687896A/en

2000-11-30 Application granted granted Critical

2000-11-30 Publication of AU727001B2 publication Critical patent/AU727001B2/en

2001-08-23 Assigned to JAGOTEC AG reassignment JAGOTEC AG Alteration of Name(s) in Register under S187 Assignors: HYAL PHARMACEUTICAL CORPORATION

2016-11-29 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000003814 drug Substances 0.000 title claims description 154
229940124597 therapeutic agent Drugs 0.000 title claims description 92
229920002683 Glycosaminoglycan Polymers 0.000 title claims description 38
230000008685 targeting Effects 0.000 title description 9
239000003795 chemical substances by application Substances 0.000 claims description 229
210000004185 liver Anatomy 0.000 claims description 197
229920002674 hyaluronan Polymers 0.000 claims description 178
229920001287 Chondroitin sulfate Polymers 0.000 claims description 120
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 118
229960003160 hyaluronic acid Drugs 0.000 claims description 118
210000002889 endothelial cell Anatomy 0.000 claims description 54
230000032258 transport Effects 0.000 claims description 52
238000000034 method Methods 0.000 claims description 48
101001054921 Homo sapiens Lymphatic vessel endothelial hyaluronic acid receptor 1 Proteins 0.000 claims description 43
102100026849 Lymphatic vessel endothelial hyaluronic acid receptor 1 Human genes 0.000 claims description 43
206010028980 Neoplasm Diseases 0.000 claims description 42
150000003839 salts Chemical class 0.000 claims description 32
230000001105 regulatory effect Effects 0.000 claims description 31
230000002829 reductive effect Effects 0.000 claims description 28
210000004027 cell Anatomy 0.000 claims description 24
201000010099 disease Diseases 0.000 claims description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 24
231100000252 nontoxic Toxicity 0.000 claims description 20
230000003000 nontoxic effect Effects 0.000 claims description 20
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 18
229910021653 sulphate ion Inorganic materials 0.000 claims description 18
KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 16
108010022164 acetyl-LDL Proteins 0.000 claims description 15
230000002222 downregulating effect Effects 0.000 claims description 15
229920002307 Dextran Polymers 0.000 claims description 14
230000037396 body weight Effects 0.000 claims description 14
AUHDWARTFSKSAC-HEIFUQTGSA-N (2S,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-(6-oxo-1H-purin-9-yl)oxolane-2-carboxylic acid Chemical compound [C@]1([C@H](O)[C@H](O)[C@@H](CO)O1)(N1C=NC=2C(O)=NC=NC12)C(=O)O AUHDWARTFSKSAC-HEIFUQTGSA-N 0.000 claims description 13
229940028843 inosinic acid Drugs 0.000 claims description 13
239000004245 inosinic acid Substances 0.000 claims description 13
241000282414 Homo sapiens Species 0.000 claims description 12
229920000288 Keratan sulfate Polymers 0.000 claims description 10
229940127089 cytotoxic agent Drugs 0.000 claims description 9
FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 claims description 8
229920000045 Dermatan sulfate Polymers 0.000 claims description 8
210000002751 lymph Anatomy 0.000 claims description 8
239000002253 acid Substances 0.000 claims description 6
239000002254 cytotoxic agent Substances 0.000 claims description 6
231100000599 cytotoxic agent Toxicity 0.000 claims description 6
201000011510 cancer Diseases 0.000 claims description 5
231100000334 hepatotoxic Toxicity 0.000 claims description 5
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 5
206010027476 Metastases Diseases 0.000 claims description 4
210000003722 extracellular fluid Anatomy 0.000 claims description 4
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims 7
230000003511 endothelial effect Effects 0.000 claims 1
229940014041 hyaluronate Drugs 0.000 description 100
WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 99
229940099552 hyaluronan Drugs 0.000 description 60
KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 57
102000005962 receptors Human genes 0.000 description 42
108020003175 receptors Proteins 0.000 description 42
230000000694 effects Effects 0.000 description 23
150000004676 glycans Chemical class 0.000 description 21
229920001282 polysaccharide Polymers 0.000 description 21
239000005017 polysaccharide Substances 0.000 description 21
241000700159 Rattus Species 0.000 description 20
210000001519 tissue Anatomy 0.000 description 19
229920002385 Sodium hyaluronate Polymers 0.000 description 18
229940010747 sodium hyaluronate Drugs 0.000 description 18
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 18
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 16
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 16
210000002966 serum Anatomy 0.000 description 13
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 12
229920000669 heparin Polymers 0.000 description 12
229960002897 heparin Drugs 0.000 description 12
102000014452 scavenger receptors Human genes 0.000 description 12
108010078070 scavenger receptors Proteins 0.000 description 12
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
239000000463 material Substances 0.000 description 11
210000002700 urine Anatomy 0.000 description 11
230000000903 blocking effect Effects 0.000 description 10
108010067787 Proteoglycans Proteins 0.000 description 9
102000016611 Proteoglycans Human genes 0.000 description 9
230000015556 catabolic process Effects 0.000 description 9
230000007246 mechanism Effects 0.000 description 9
229940079593 drug Drugs 0.000 description 8
229960000905 indomethacin Drugs 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 7
239000012634 fragment Substances 0.000 description 7
238000001727 in vivo Methods 0.000 description 7
210000002540 macrophage Anatomy 0.000 description 7
210000000056 organ Anatomy 0.000 description 7
102000000844 Cell Surface Receptors Human genes 0.000 description 6
108010001857 Cell Surface Receptors Proteins 0.000 description 6
238000006731 degradation reaction Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
239000000243 solution Substances 0.000 description 6
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
239000012506 Sephacryl® Substances 0.000 description 5
229960005070 ascorbic acid Drugs 0.000 description 5
235000010323 ascorbic acid Nutrition 0.000 description 5
239000011668 ascorbic acid Substances 0.000 description 5
238000009826 distribution Methods 0.000 description 5
238000009472 formulation Methods 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 5
210000003734 kidney Anatomy 0.000 description 5
-1 methyl CCNU Chemical compound 0.000 description 5
239000000203 mixture Substances 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
108090000623 proteins and genes Proteins 0.000 description 5
230000036325 urinary excretion Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 4
208000033222 Biliary cirrhosis primary Diseases 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
208000012654 Primary biliary cholangitis Diseases 0.000 description 4
230000008033 biological extinction Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
239000000872 buffer Substances 0.000 description 4
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 4
230000007423 decrease Effects 0.000 description 4
150000002148 esters Chemical class 0.000 description 4
238000002372 labelling Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
238000004519 manufacturing process Methods 0.000 description 4
230000001394 metastastic effect Effects 0.000 description 4
206010061289 metastatic neoplasm Diseases 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
230000001613 neoplastic effect Effects 0.000 description 4
VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 description 4
238000011084 recovery Methods 0.000 description 4
159000000000 sodium salts Chemical class 0.000 description 4
230000007306 turnover Effects 0.000 description 4
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
108010003272 Hyaluronate lyase Proteins 0.000 description 3
102000001974 Hyaluronidases Human genes 0.000 description 3
102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 3
108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
108091006629 SLC13A2 Proteins 0.000 description 3
229930003268 Vitamin C Natural products 0.000 description 3
239000000061 acid fraction Substances 0.000 description 3
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 3
239000003242 anti bacterial agent Substances 0.000 description 3
229940124599 anti-inflammatory drug Drugs 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
229940041181 antineoplastic drug Drugs 0.000 description 3
230000008901 benefit Effects 0.000 description 3
102000023732 binding proteins Human genes 0.000 description 3
108091008324 binding proteins Proteins 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000002981 blocking agent Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
229960001927 cetylpyridinium chloride Drugs 0.000 description 3
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
229960004316 cisplatin Drugs 0.000 description 3
206010012601 diabetes mellitus Diseases 0.000 description 3
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 3
229960003883 furosemide Drugs 0.000 description 3
229940097043 glucuronic acid Drugs 0.000 description 3
229960002773 hyaluronidase Drugs 0.000 description 3
230000006872 improvement Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
210000005229 liver cell Anatomy 0.000 description 3
210000001165 lymph node Anatomy 0.000 description 3
229960002009 naproxen Drugs 0.000 description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 3
238000002203 pretreatment Methods 0.000 description 3
230000008569 process Effects 0.000 description 3
150000003180 prostaglandins Chemical class 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
230000010837 receptor-mediated endocytosis Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000003637 steroidlike Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 3
239000003053 toxin Substances 0.000 description 3
231100000765 toxin Toxicity 0.000 description 3
108700012359 toxins Proteins 0.000 description 3
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Chemical compound OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
229930003231 vitamin Natural products 0.000 description 3
239000011782 vitamin Substances 0.000 description 3
235000013343 vitamin Nutrition 0.000 description 3
229940088594 vitamin Drugs 0.000 description 3
235000019154 vitamin C Nutrition 0.000 description 3
239000011718 vitamin C Substances 0.000 description 3
150000003722 vitamin derivatives Chemical class 0.000 description 3
ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
102100032912 CD44 antigen Human genes 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
229920002567 Chondroitin Polymers 0.000 description 2
108010036941 Cyclosporins Proteins 0.000 description 2
241000792859 Enema Species 0.000 description 2
229940123457 Free radical scavenger Drugs 0.000 description 2
229930182566 Gentamicin Natural products 0.000 description 2
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
108010013214 Hyaluronan Receptors Proteins 0.000 description 2
102000018866 Hyaluronan Receptors Human genes 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
208000010159 IgA glomerulonephritis Diseases 0.000 description 2
206010021263 IgA nephropathy Diseases 0.000 description 2
239000007836 KH2PO4 Substances 0.000 description 2
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
229930182816 L-glutamine Natural products 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 description 2
102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
239000012979 RPMI medium Substances 0.000 description 2
201000011032 Werner Syndrome Diseases 0.000 description 2
235000010724 Wisteria floribunda Nutrition 0.000 description 2
230000005856 abnormality Effects 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
230000009471 action Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
239000002260 anti-inflammatory agent Substances 0.000 description 2
229960000686 benzalkonium chloride Drugs 0.000 description 2
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
229940124630 bronchodilator Drugs 0.000 description 2
DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
239000006071 cream Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
229930182912 cyclosporin Natural products 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
230000003413 degradative effect Effects 0.000 description 2
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
230000009429 distress Effects 0.000 description 2
239000002934 diuretic Substances 0.000 description 2
229940030606 diuretics Drugs 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000007920 enema Substances 0.000 description 2
229940095399 enema Drugs 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
229960002518 gentamicin Drugs 0.000 description 2
229960002442 glucosamine Drugs 0.000 description 2
230000003779 hair growth Effects 0.000 description 2
210000003494 hepatocyte Anatomy 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
201000006747 infectious mononucleosis Diseases 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
229940079322 interferon Drugs 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
208000028867 ischemia Diseases 0.000 description 2
229960004752 ketorolac Drugs 0.000 description 2
OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 description 2
210000001865 kupffer cell Anatomy 0.000 description 2
230000003902 lesion Effects 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
230000003908 liver function Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960003632 minoxidil Drugs 0.000 description 2
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
230000004899 motility Effects 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
229950006780 n-acetylglucosamine Drugs 0.000 description 2
230000000926 neurological effect Effects 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
229940087419 nonoxynol-9 Drugs 0.000 description 2
229920004918 nonoxynol-9 Polymers 0.000 description 2
210000004738 parenchymal cell Anatomy 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
230000010412 perfusion Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
230000009325 pulmonary function Effects 0.000 description 2
239000002516 radical scavenger Substances 0.000 description 2
239000000700 radioactive tracer Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
206010039073 rheumatoid arthritis Diseases 0.000 description 2
231100000241 scar Toxicity 0.000 description 2
238000010008 shearing Methods 0.000 description 2
238000005549 size reduction Methods 0.000 description 2
238000001542 size-exclusion chromatography Methods 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000012453 sprague-dawley rat model Methods 0.000 description 2
230000008961 swelling Effects 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
230000002792 vascular Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000008035 Back Pain Diseases 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
229910001369 Brass Inorganic materials 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
229920001268 Cholestyramine Polymers 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
102100021906 Cyclin-O Human genes 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000897441 Homo sapiens Cyclin-O Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
108010007622 LDL Lipoproteins Proteins 0.000 description 1
102000007330 LDL Lipoproteins Human genes 0.000 description 1
241001071864 Lethrinus laticaudis Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
206010061137 Ocular toxicity Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102000019197 Superoxide Dismutase Human genes 0.000 description 1
108010012715 Superoxide dismutase Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
206010044245 Toxic optic neuropathy Diseases 0.000 description 1
208000030886 Traumatic Brain injury Diseases 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
206010000496 acne Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000003945 anionic surfactant Substances 0.000 description 1
210000002159 anterior chamber Anatomy 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
210000001742 aqueous humor Anatomy 0.000 description 1
229960002274 atenolol Drugs 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
238000003287 bathing Methods 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000010951 brass Substances 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
239000000168 bronchodilator agent Substances 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
208000020670 canker sore Diseases 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
210000003161 choroid Anatomy 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
210000002314 coated vesicle Anatomy 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
239000002131 composite material Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000003433 contraceptive agent Substances 0.000 description 1
230000002254 contraceptive effect Effects 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229960000265 cromoglicic acid Drugs 0.000 description 1
210000000695 crystalline len Anatomy 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960001259 diclofenac Drugs 0.000 description 1
DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
210000002767 hepatic artery Anatomy 0.000 description 1
229960001680 ibuprofen Drugs 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000008595 infiltration Effects 0.000 description 1
238000001764 infiltration Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000000554 iris Anatomy 0.000 description 1
229960004384 ketorolac tromethamine Drugs 0.000 description 1
BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000003141 lower extremity Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
210000003712 lysosome Anatomy 0.000 description 1
230000001868 lysosomic effect Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
238000004264 monolayer culture Methods 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
229960001597 nifedipine Drugs 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
231100000327 ocular toxicity Toxicity 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
231100000915 pathological change Toxicity 0.000 description 1
230000036285 pathological change Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
238000009781 safety test method Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
241000894007 species Species 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000004127 vitreous body Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU76878/96A 1995-12-01 1996-11-29 Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS) Ceased AU727001B2 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
CA2164260		1995-12-01
CA002164260A CA2164260C (en)	1995-12-01	1995-12-01	Targeting of dosages of medicines and therapeutic agents
CA 2173037 CA2173037A1 (en)	1996-03-29	1996-03-29	Targeting of dosages of medicines and therapeutic agents and other glycosaminoglycans (gags)
CA2173037		1996-03-29
PCT/CA1996/000793 WO1997020564A1 (en)	1995-12-01	1996-11-29	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (gags)

Publications (2)

Publication Number	Publication Date
AU7687896A AU7687896A (en)	1997-06-27
AU727001B2 true AU727001B2 (en)	2000-11-30

Family

ID=25678243

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU76878/96A Ceased AU727001B2 (en)	1995-12-01	1996-11-29	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)

Country Status (11)

Country	Link
EP (1)	EP0869798A1 (pt)
JP (1)	JP2000513707A (pt)
KR (1)	KR19990071628A (pt)
AU (1)	AU727001B2 (pt)
BR (1)	BR9611671A (pt)
HU (1)	HUP9901935A3 (pt)
IL (1)	IL124647A0 (pt)
MX (1)	MX9804343A (pt)
NO (1)	NO982441L (pt)
PL (1)	PL326970A1 (pt)
WO (1)	WO1997020564A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITPD940054A1 (it) *	1994-03-23	1995-09-23	Fidia Advanced Biopolymers Srl	Polisaccaridi solfatati
CN100374163C (zh)	1999-01-13	2008-03-12	阿尔凯米亚肿瘤学私人有限公司	增强药物功效的组合物
AUPQ879500A0 (en)	2000-07-14	2000-08-10	Meditech Research Limited	Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease
US9066919B2 (en)	2000-07-14	2015-06-30	Alchemia Oncology Pty Limited	Hyaluronan as a chemo-sensitizer in the treatment of cancer
EP1912658B1 (en) *	2005-07-27	2017-01-25	Alchemia Oncology Pty Limited	Therapeutic protocols using hyaluronan
EP1922077A4 (en)	2005-09-07	2013-03-06	Alchemia Oncology Pty Ltd	THERAPEUTIC COMPOSITIONS WITH HYALURON AND THERAPEUTIC ANTIBODIES AND TREATMENT PROCEDURES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996004058A1 (en) *	1994-07-29	1996-02-15	International Fluid Separation Pty. Ltd.	Separation apparatus and method
WO1996006622A1 (en) *	1991-07-03	1996-03-07	Hyal Pharmaceutical Corporation	Hyaluronic acid and derivatives for modulation of cellular activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease

1996
- 1996-11-29 WO PCT/CA1996/000793 patent/WO1997020564A1/en not_active Ceased
- 1996-11-29 PL PL96326970A patent/PL326970A1/xx unknown
- 1996-11-29 EP EP96939774A patent/EP0869798A1/en not_active Ceased
- 1996-11-29 KR KR1019980703904A patent/KR19990071628A/ko not_active Ceased
- 1996-11-29 HU HU9901935A patent/HUP9901935A3/hu unknown
- 1996-11-29 AU AU76878/96A patent/AU727001B2/en not_active Ceased
- 1996-11-29 IL IL12474796A patent/IL124647A0/xx not_active IP Right Cessation
- 1996-11-29 BR BR9611671-4A patent/BR9611671A/pt not_active Application Discontinuation
- 1996-11-29 JP JP09520818A patent/JP2000513707A/ja not_active Ceased
1998
- 1998-05-28 NO NO982441A patent/NO982441L/no unknown
- 1998-06-01 MX MX9804343A patent/MX9804343A/es unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1996006622A1 (en) *	1991-07-03	1996-03-07	Hyal Pharmaceutical Corporation	Hyaluronic acid and derivatives for modulation of cellular activity
WO1996004058A1 (en) *	1994-07-29	1996-02-15	International Fluid Separation Pty. Ltd.	Separation apparatus and method

Also Published As

Publication number	Publication date
HUP9901935A3 (en)	2001-04-28
AU7687896A (en)	1997-06-27
EP0869798A1 (en)	1998-10-14
PL326970A1 (en)	1998-11-09
JP2000513707A (ja)	2000-10-17
NO982441D0 (no)	1998-05-28
KR19990071628A (ko)	1999-09-27
WO1997020564A1 (en)	1997-06-12
MX9804343A (es)	1998-09-30
BR9611671A (pt)	1999-12-28
HUP9901935A2 (hu)	1999-11-29
IL124647A0 (en)	1998-12-06
NO982441L (no)	1998-05-28

Publication	Publication Date	Title
AP618A (en)	1997-10-10	Modulation of cellular activity by administering a form of hyaluronic acid.
Scale et al.	1994	Viscosupplementation of osteoarthritic knees with hylan: a treatment schedule study
US8343942B2 (en)	2013-01-01	Methods for treating interstitial cystitis
US5614506A (en)	1997-03-25	Use of hyaluronic acid and forms to prevent arterial restenosis
CN102114031A (zh)	2011-07-06	使用于炎症性肠疾病治疗和预防的透明质酸混合物
AU2002221528B2 (en)	2007-03-22	Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis
HU220758B1 (hu)	2002-05-28	Eljárás hialuronsavat és nem szteroid gyulladásgátlót tartalmazó, rák kezelésére alkalmas gyógyászati készítmények előállítására
IL124977A (en)	2006-10-31	Oral pharmaceutical compositions containing forms of hyaluronic acid for treating restenosis
US5674857A (en)	1997-10-07	Use of hyaluronic acid to repair ischemia reperfusion damage
US5834444A (en)	1998-11-10	Hyaluronic acid and salts thereof inhibit arterial restenosis
CA2175282A1 (en)	1997-10-30	Use of forms of hyaluronic acid (ha) for the treatment of cancer
JP5636225B2 (ja)	2014-12-03	炎症性腸疾患（ｉｂｄ）の治療及び予防に使用するための医薬組成物
AU727001B2 (en)	2000-11-30	Targeting of dosages of medicine and therapeutic agents and other glycosaminoglycans (GAGS)
US5817644A (en)	1998-10-06	Targeting of dosages of medicine and therapeutic agents
EP0874624B1 (en)	2003-12-03	Hyaluronic acid receptors binding agents and their use for treating tumors or restenosis
AP448A (en)	1996-01-18	Use of hyaluronic acid and forms to prevent arterial restenosis.
CA2164260C (en)	2001-10-09	Targeting of dosages of medicines and therapeutic agents
CA2089621A1 (en)	1994-08-17	Formulations containing hyaluronic acid
Gustafson	1997	The influence of sulfated polysaccharides on the circulating levels of hyaluronan
CA2173037A1 (en)	1997-09-30	Targeting of dosages of medicines and therapeutic agents and other glycosaminoglycans (gags)
CA2156013A1 (en)	1997-02-15	Modulation of cellular activity
CA2145605A1 (en)	1996-09-28	Modulation of cellular activity
CA2166154A1 (en)	1997-06-28	Binding agents and the use thereof
WO1998027990A1 (en)	1998-07-02	Methods of elevating amounts of hyaluronan in the human body
CA2194750A1 (en)	1998-07-09	Methods of elevating amounts of hyaluronan in the human body

Legal Events

Date	Code	Title	Description
2001-03-29	FGA	Letters patent sealed or granted (standard patent)
2001-08-23	PC	Assignment registered	Owner name: JAGOTEC AG Free format text: FORMER OWNER WAS: HYAL PHARMACEUTICAL CORPORATION

Date

Code

Title

Description

2001-03-29

FGA

Letters patent sealed or granted (standard patent)

2001-08-23

Assignment registered

Owner name: JAGOTEC AG

Free format text: FORMER OWNER WAS: HYAL PHARMACEUTICAL CORPORATION